Skip to content
inentertainment.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Damora Therapeutics, Inc.
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 10, 2026
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
August 5, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026
Damora Announces Redomestication from Delaware to Cayman Islands
July 17, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 1, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 24, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 23, 2026